Reduced progression of diabetic microvascular complications with islet cell transplantation compared with intensive medical therapy

Transplantation

Volumn 91, Issue 3, 2011, Pages 373-378

  Thompson, David M ^a   Meloche, Mark ^a   Ao, Ziliang ^a   Paty, Breay ^a   Keown, Paul ^a   Shapiro, R Jean ^a   Ho, Stephen ^a   Worsley, Dan ^a   Fung, Michelle ^a   Meneilly, Graydon ^a   Begg, Iain ^a   Al Mehthel, Mohammed ^a   Kondi, Joma ^a   Harris, Claire ^a   Fensom, Blake ^a   Kozak, Sharon E ^a   Tong, Suet On ^a   Trinh, Mary ^a   Warnock, Garth L ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Diabetic complications; Islet cell transplantation; Type 1 diabetes

Indexed keywords

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CROSSOVER PROCEDURE; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE COURSE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; MALE; NERVE CONDUCTION; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL;

ADULT; COHORT STUDIES; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DIABETIC NEUROPATHIES; DIABETIC RETINOPATHY; DISEASE PROGRESSION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; INSULIN; ISLETS OF LANGERHANS TRANSPLANTATION; MALE; MICROVESSELS; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 79951508861     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31820437f3     Document Type: Article

References (55)

1. Fiorina P, Shapiro AJM, Ricordi C, et al. The clinical impact of islet transplantation. Am J Transplant 2009; 9: 1900.
2. American Diabetes Association. Position statement. Nephropathy in diabetes. Diabetes Care 2004; 27: S79.
3. Vinik AI, Mehrabyan A. Diabetic neuropathies. Med Clin North Am 2004; 88: 947.
4. Porta M, Bandello F. Diabetic retinopathy: A clinical update. Diabeto-logia 2002; 45: 1617.
5. DCCT Research Group. Hypoglycemia in the diabetes control and complications trial. Diabetes 1997; 46: 271.
6. DCCT/EDIC. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy. JAMA 2003; 290: 2159.
7. American Academy of Ophthalmology. Preferred practice pattern. Diabetic Retinopathy. Lippincott, Williams & Wilkins. 2003.
8. Louis TA, Lavori PW, Bailar JC, et al. Crossover and self-controlled designs in clinical research. In: Bailar JC, Mosteller F, eds. Medical uses of statistics [ed. 2]. Boston, MA, NEJM Books 1992.
9. Rossing P. The changing epidemiology of diabetic microangiopathy in type 1 diabetes. Diabetologia 2005; 48: 1439.
10. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, stratification, and classification. Am J Kidney Disease 2002; 39: S1.
11. Fung MA, Warnock GL, Ao Z, et al. The effect of medical therapy and islet cell transplantation on diabetic nephropathy: An interim report. Transplantation 2007; 84: 17.
12. Bellin MD, Kandaswamy R, Parkey J, et al. Prolonged insulin independence after islet allotransplants in recipients with type 1 diabetes. Am J Transplant 2008; 8: 2463.
13. Senior PA, Zeman M, Paty BW, et al. Changes in renal function after clinical islet transplantation: Four-year observational study. Am J Transplant 2007; 7: 91.
14. Maffi P, Bertuzzi F, De Taddeo F, et al. Kidney function after islet transplant aloneintype1diabetes: Impactofimmunosuppressive therapy on progression of diabetic nephropathy. Diabetes Care 2007; 30: 1150.
15. Shapiro AM, Ricordi C, Hering BJ, et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med 2006; 355: 1318.
16. Molitch ME, Steffes M, Sun W, et al. Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study. Diabetes Care 2010; 33: 1536.
17. Naesens M, Kuypers RJ, Sarwal M. Calcineurin inhibitor nephrotoxic-ity. Clin J Am Soc Neph 2009; 4: 481.
18. Marti HP, Frey FJ. Nephrotoxicity ofrapamycin: Anemerging problem in clinical medicine. Nephrol Dial Transplant 2005; 20: 13.
19. Kaplan B, Schold J, Srinivas T, et al. Effect of sirolimus withdrawal in patients with deteriorating renal function. Am J Tranplant 2004; 4: 1709.
20. Kobashigawa JA, Miller LW, Russell SD, et al. Tacrolimus with myco-phenolate mefetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplantation 2006; 6: 1377.
21. Gallon L, Perico N, Dimitrov BD, et al. Long-term renal allograft function on a tacrolimus-based, pred-free maintenance immumosuppres-sion comparing sirolimus vs MMF. Am J Transplant 2006; 6: 1617.
22. Mendez R, Gonwa T, Yang HC, et al. A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: Results at 1 year. Transplantation 2005; 80: 303.
23. Senior PA, Paty BW, Cockfield SM, et al. Proteinuria developing after clinical islet transplantation resolves with sirolimus withdrawal and increased tacrolimus dosing. Am J Transplant 2005; 5: 2318.
24. Thompson DM, Begg IS, Harris C, et al. Reduced progression of diabetic retinopathy after islet cell transplantation compared with intensive medical therapy. Transplantation 2008; 85: 1400.
25. DCCT Research Group. The effect ofintensive treatmentofdiabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus. N Engl J Med 1993; 329: 977.
26. Klein R, Klein BEK, Moss SE, et al. The Wisconsin epidemiologic study of diabetic retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type1 diabetes. Ophthalmology 1998; 105: 1801.
27. Davis MD, Fisher MR, Gangnon RE, et al. Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early treat-ment diabetic retinopathy study report #18. Invest Ophthalmol Vis Sci 1998; 39: 233.
28. Pearce IA, Ilango B, Sells RA, et al. Stabilisation of diabetic retinopathy following simultaneous pancreas and kidney transplant. Br J Ophthal-mol 2000; 84: 736.
29. Giannarelli R, Coppelli A, Sartini M, et al. Effects of pancreas-kidney transplantation on diabetic retinopathy. Transplant Int 2005; 18: 619.
30. Wilkinson CP, Ferris FL, Klein RE,etal. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 2003; 110: 1677.
31. Grading diabetic retinopathy from stereoscopic color fundus photographs-An extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Reti-nopathy Study Research Group. Ophthalmology 1991; 98: 786.
32. Del Carro U, Fiorina P, Amadioi S, et al. Evaluation of polyneuropathy markers in type 1 diabetic kidney transplant patients and effects of islet transplantation. Diabetes Care 2007; 30: 3063.
33. Lee TC, Barshes NR, O'Mahony CA, et al. The effect of pancreatic islet transplantation on progression of diabetic retinopathy and neuropathy. Transplant Proc 2005; 37: 2263.
34. Navarro X, Sutherland DER, Kennedy WR. Long-term effects of pancreatic transplantation on diabetic neuropathy. Ann Neurol 2003; 42: 727.
35. Warram JH, Scott LJ, Hanna LS, et al. Progression of microalbumin-uria to proteinuria in type 1 diabetes. Diabetes 2000; 49: 94.
36. Johansson B-L, Borg K, Fernqvist-Forbes E, et al. Beneficial effects of C-peptide on incipient nephropathy and neuropathy in patients with type 1 diabetes mellitus. Diabetic Med 2000; 17: 181.
37. Fiorina P, Folli F, Zerbini G, et al. Islet transplantation is associated with improvement of renal function among uremic patients with type 1 diabetes mellitus and kidney transplants. J Am Soc Nephrol 2003; 14: 2150.
38. The ACCORD study group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. New Engl J Med 2010; 362: 1575.
39. LehmannR,Spinas GA, MoritzW,etal. Has time come for new goals in human islet transplantation? Am J Transplant 2008; 8: 1096.
40. Van Dijk PCW, Jager KJ, Stengel B,etal. Renal replacement therapy for diabetic end-stage renal disease: Data from 10 registries in Europe (1991-2000). Kidney Int 2005; 67: 1489.
41. The DCCT Research Group. Implementationof treatment protocols in the diabetes control and complications trial. Diabetes Care 1995; 18: 361.
42. Thompson DM, Kozak SE, Sheps S. Insulin adjustment by a diabetes nurse educator improves glucose control in insulin-requiring diabetic patients: A randomized trial. Can Med Assoc J 1999; 161: 859.
43. Warnock GL, Meloche M, Thompson DM, et al. Improved human pancreatic islet isolation for a prospective cohort study of islet trans-plantationvs best medical therapy in type 1diabetes mellitus. Arch Surg 2005; 140: 735.
44. Perrone RD, Steinman TI, Beck G, et al. Utility of radioisotopic filtration markers in chronic renal insufficiency: Simultaneous comparison of 125I-iothalamate, 169Yb-DTPA, 99mTc-DTPA and inulin. The Modification of Diet in Renal Disease Study. Am J Kidney Dis 1990; 26: 224.
45. Blaufox MD, Aurell M, Bubeck B, et al. Report of the radionuclides in nephrourology committee on renal clearance. J Nucl Med 1996; 37: 1883.
46. Mariat C, Alamertine E, Barthelemy J-C, et al. Assessing renal graft function in clinical trials: Can tests predicting glomerular filtration rate substitute for a reference method? Kidney Int 2004; 65: 289.
47. K/DOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Disease 2007; 49(s2): S1.
48. Perkins BA, Nelson RG, Ostrander BEP, et al. Detection of renal function in patients with diabetes and normal or elevated GFR by serial measurements of serum cystatin C concentration: Results of a 4-year follow-up study. J Am Soc Nephrol 2005; 16: 1404.
49. Levey AS, Bosch JP, Lewis JB, et al.A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation: Modification of diet in renal disease study group. Ann Intern Med 1999; 130: 461.
50. Hsu C-Y, Chertow GM, Curhan GC. Methodological issuesin studying the epidemiology of mild to moderate chronic renal insufficiency. Kidney Int 2002; 61: 1567.
51. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, stratification, and classification. Am J Kidney Dis 2002; 39(2 suppl 1): S1.
52. Early Treatment of Diabetic Retinopathy Study Research Group. Pho-tocoagulation for diabetic macular edema: ETDRS report number 1. Arch Ophthalmol 1985; 103: 1796.
53. Claus D,Mustafa C, Vogel W, et al. Assessment ofdiabetic neuropathy: Definition of norm and discrimination of abnormal nerve function. Muscle Nerve 1993; 16: 757.
54. Proceedings of a consensus development conference on standardized measures in diabetic neuropathy. Diabetes Care 1992; 15: 1080.
55. American Diabetes Association. Technical Review. Standardized measures in diabetic neuropathy. Diabetes Care 1995; 18(suppl 1): 59.